Literature DB >> 1661134

Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity.

L D Teeter1, T Eckersberg, Y Tsai, M T Kuo.   

Abstract

Recent studies have revealed that the expression of P-glycoprotein/multidrug resistance genes is crucial for the development of resistance to a number of lipophilic cancer chemotherapeutic agents. To better understand the regulatory mechanisms of pgp gene expression, we isolated and characterized a DNA fragment containing the 5' portion of a Chinese hamster pgp gene. DNA sequence analysis revealed that this gene is pgp1, the hamster homologue of murine mdr3/mdr1a. This gene is expressed at a higher level in intestines than in kidney and liver, consistent with the expression pattern for the murine mdr3/mdr1a gene. The major transcription start site, determined by the S1 nuclease protection, RNase protection, and primer extension methods, lies 67 nucleotides upstream of the murine and human downstream transcription start site. A chimera containing 101 base pairs upstream from this start site and the chloramphenicol acetyltransferase (CAT) gene was able to direct CAT expression in transient transfection experiments. The AP-1 site, located at -48 base pairs, was crucial for the full pgp1 promoter activity, as demonstrated by site-directed mutagenesis of this site, enhancement of the CAT expression by cotransfection with the expression vectors encoding c-Jun/c-Fos genes, but sequestration with those containing retinoic acid receptor genes. The sequestration effect could be partially abolished when c-Jun/c-Fos genes were also included in cotransfection. An AP-1 or AP-1-like site is also present at the same location in both human and mouse mdr homologues. The involvement of AP-1 in the expression of mammalian pgp1-class genes is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661134

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases.

Authors:  E de Kant; I Heide; C Thiede; R Herrmann; C F Rochlitz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 2.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

3.  Ribozyme-mediated reversal of the multidrug-resistant phenotype.

Authors:  K J Scanlon; H Ishida; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

4.  Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases.

Authors:  M Volm; G van Kaick; J Mattern
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

5.  Activation of the mouse mdr3 gene by insertion of retroviruses in multidrug-resistant P388 tumor cells.

Authors:  P Lepage; A Devault; P Gros
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

6.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

7.  Transcriptional regulation of MDR genes.

Authors:  K W Scotto; D A Egan
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

8.  Influence of exogenous RAR alpha gene on MDR1 expression and P-glycoprotein function in human and rodent cell lines.

Authors:  T P Stromskaya; E Y Rybalkina; A A Shtil; T N Zabotina; N A Filippova; A A Stavrovskaya
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

9.  P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia.

Authors:  A Sauerbrey; F Zintl; M Volm
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

10.  Protein expression profiles indicative for drug resistance of non-small cell lung cancer.

Authors:  M Volm; R Koomägi; J Mattern; T Efferth
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.